Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials.
| Image |  |
|---|---|
| Description | scientific article published on 31 January 2018 |
| Author/s |
author: Michael LaValley |
| Publication date | January 31, 2018 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |